New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
07:17 EDTMDCOThe Medicines Co. downgraded to Market Perform from Outperform at Leerink
Leerink downgraded The Medicines Co. to Market Perform citing uncertainty regarding Angiomax estimates into the appeals trial. The firm lowered its price target for shares to $27 from $30.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use